Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorder
In a Phase 1 trial, patients with an advanced or aggressive form of systemic mastocytosis (AdvSM), a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational ...
Dec 10, 2017
0
4